You haven't searched anything yet.
Location(s): Netherlands
Level of position: Senior Manager
Position type: Office-based
Reporting Line: Director, International Supply Chain
How will your role help us transform hope into reality?
The International Supply Chain Lead, reporting to the Director International Supply chain, will collaborate closely with external partners for secondary packaging and distribution of Commercial finished goods, including serialization and order to cash services. This role will interact with partners within Blueprint including Supply Planning (US), Finance, Quality and Regulatory Affairs. This position is critical for ensuring packaging components, and packaging processes meet regulatory, quality and brand requirements while maintaining continuity of supply. The International Supply Chain Lead will require demonstrated experience of supply chain and project leadership, allowing for the ability to influence partners within and outside of the Technical Operations group at Blueprint Medicines.
What will you do?
What minimum qualifications do we require?
What additional qualifications will make you a stronger candidate?
Why Blueprint?
At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators – the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success.
This is the place where the extraordinary becomes reality, and you could be part of it.
Patients are waiting. Are you ready to make the leap?
Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing an approved medicine to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition.
*Blueflex is our operating model which optimizes culture, productivity, & flexibility by maximizing the critical strengths of in-person work with the benefits of added flexibility. Blueflex allows for mix of in-office and remote work, enables flexibility to meet individual and business needs and makes effective use of our facilities and resources. It is a culture enhancer.
#LI-Hybrid
#LI-NJ1
Full Time
Pharmaceutical
$104k-136k (estimate)
05/04/2024
07/11/2024
blueprintmedicines.com
CAMBRIDGE, MA
200 - 500
2011
Public
JEFFREY W ALBERS
$500M - $1B
Pharmaceutical
Blueprint Medicines is an oncology firm that develops kinase inhibitors for genomically defined cancer subsets.